Pluri Inc.

Independent Proxy Advisory Firm, Institutional Shareholder Services, ("ISS") Recommends Shareholders Vote "For" the Proposed Plan of Arrangement with Quantum eMotion Corp.

ISS has recommended Plurilock shareholders vote FOR the plan of arrangement under which Quantum eMotion will acquire all outstanding Plurilock shares. Shareholders will receive $0.084 in cash plus 0.0763 of a QeM common share per Plurilock share. ISS said the mixed consideration offers immediate cash value plus upside participation in the combined company. The special meeting is set for November 18, 2026, with the proxy voting deadline at 10:00 a.m. Vancouver time on November 16; the board unanimously supports the deal.

•12h ago

Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company

Pluri announced that Chairman and largest shareholder Alejandro Weinstein has agreed to acquire the company's loan from the European Investment Bank, replacing the EIB as lender under existing arrangements. Pluri and Weinstein intend to negotiate revised loan terms and present a long-term resolution plan, which management says allows it to stay focused on commercialization and strategic growth. The deal was approved by a special independent committee and a majority of independent directors, and Weinstein framed it as the first step in a broader series of actions to reshape the company.

•13d ago

Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity

Ever After Foods and Roslin Technologies reported results from their joint cultivated meat production program, achieving cell density above 150 million cells/ml and 326gr/L wet biomass on EAF's Edible Packed Bed platform. Compared to a stirred-tank suspension benchmark, the platform showed 19x higher dry biomass and cultivated protein productivity and 11x higher wet biomass productivity, driven by 5x higher cell density plus a 4x per-cell gain in protein and biomass output. All metrics were achieved with an edible plant-based scaffold under 2% of final product weight, and the partners are continuing scale-up work. The milestone advances the commercialization path for the cultivated-meat platform but carries no disclosed financial impact.

•21d ago

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri's majority-owned subsidiary, Ever After Foods, acquired Fishway BV, a Belgium-based biotechnology company specializing in aquatic cell biology and animal-component-free media, to expand its cultivated-protein platform. The transaction is supported by a $2 million strategic investment through a SAFE Agreement, intended to fund ongoing platform development and commercialization activities. Management expects the acquisition to bolster EAF's European footprint and enhance its ability to support food and ingredient clients in scaling production.

•2mo ago

Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform

Ever After Foods acquired Fishway to expand its industrial protein manufacturing platform, integrating aquatic cell lines and animal-component-free media expertise. Concurrently, the company secured a $2 million strategic investment to support continued commercialization and platform expansion. The integration shortens development cycles and accelerates commercialization, with an initial focus on cultivated functional protein ingredients for premium pet food.

•2mo ago

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Pluri's subsidiary Cellav completed cosmetic regulatory registration in the UK for Regenativo+, enabling the commercial launch of its regenerative aesthetics product in a market estimated at $900 million annually. This milestone complements recent US regulatory progress and advances the company's strategy to establish a global presence in the regenerative aesthetics and longevity markets. Management highlighted the registration as a validation of its strategy to translate regenerative science into market-ready products, with active commercial discussions underway in the UK.

•3mo ago

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Pluri Chairman Alejandro Weinstein has increased his ownership stake to over 30% after investing more than $17 million cumulatively over the past year. The accumulation includes a $1.25 million advance investment in June 2026, aligning with the company's strategic pivot toward commercial execution in the U.S. longevity market. CEO Yaky Yanay characterized the investment as a strong validation of the company's strategy amid growing inbound interest for product purchases and collaborations.

•3mo ago

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri Inc. announced that its subsidiary Cellav has completed U.S. cosmetic product listings for two flagship regenerative aesthetic products, Regenativo+ and Placento+. The listings clear the regulatory path for a commercial launch in the United States during 2026, marking the transition of Cellav from product development to commercialization. Cellav is now in active discussions with U.S. distributors and clinic networks to secure initial commercial orders, targeting the rapidly expanding U.S. medical aesthetics market projected to reach $90 billion by 2030.

•5mo ago